- 24/7 Wall St.•20 hours ago
aTyr Pharma watched its shares climb early on Monday after the company announced that its product candidate Resolaris was granted Fast Track designation by the FDA.
- PR Newswire•22 hours agoaTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)
SAN DIEGO, Oct. 24, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris™ was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD), making it the first known therapeutic candidate for the treatment of FSHD to receive the designation. Resolaris, a designated Orphan Drug in FSHD, is currently being studied in a Phase 1b/2 clinical program. "This Fast Track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical needs, represents another step forward for our rare muscle disease franchise," said John Mendlein, PhD, CEO of aTyr Pharma.
aTyr Pharma Inc. (LIFE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||1.60 x 300|
|Ask||3.40 x 100|
|Day's Range||3.00 - 3.25|
|52wk Range||2.48 - 13.26|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.22|
|Avg Vol (3m)||196,452|
|Dividend & Yield||N/A (N/A)|